Oncologist-approved cancer information from the American Society of Clinical Oncology

Multiple Myeloma

News and highlights from ASCO Annual Meetings.


Category :
Year :
 
 
Adding Thalidomide to Standard Treatment Extends Survival for Older Patients with Multiple Myeloma
June 4, 2006

Adding thalidomide (Thalomid) to the standard treatment of melphalan (Alkeran) and prednisone (MP, a class of drug similar to cortisone) significantly improves survival for newly-diagnosed patients age 65 and older with multiple myeloma, according to a new study. This is the first and only clinical trial to compare MP and thalidomide with either MP alone or a stem cell transplantation.
New Drug Delays Cancer Progression in Patients With Relapsed Multiple Myeloma
June 5, 2004

Results of a phase III clinical trial show that bortezomib (Velcade) improves patient survival and slows the progression of multiple myeloma that has come back after initial treatment (relapsed). Bortezomib also appears to cause fewer side effects in patients than a current standard treatment, dexamethasone.
<<Previous | Page 1 of 1 | Next>>